Table 7.

Tofacitinib versus tocilizumab: comparison of CDAI-based improvements at 12 months in patients with RA after IPTW adjustment for time-varying confounders

	bDMARD-naïve patients with RA		Previous bDMARD-failure patients with RA
	Adjusted OR* (95% CI)	P value	Adjusted OR* (95% CI)	P value
Remission (CDAI ≤2.8)	4.13 (2.18 to 7.82)	<0.001	1.12 (0.51 to 2.41)	0.78
Remission or low CDAI (≤10)	2.57 (1.23 to 5.35)	0.012	1.11 (0.63 to 1.94)	0.73
CDAI85† (major response)	4.22 (2.26 to 7.88)	<0.001	0.85 (0.42 to 1.70)	0.64
CDAI70† (moderate response)	3.27 (1.72 to 6.23)	<0.001	1.38 (0.76 to 2.50)	0.29
CDAI50† (minor response)	1.77 (0.85 to 3.69)	0.13	1.18 (0.67 to 2.08)	0.56
MCID-based improvement‡	2.99 (1.19 to 7.50)	0.020	0.79 (0.43 to 1.45)	0.45

*IPTW-adjusted ORs (95% CI) of tofacitinib versus tocilizumab were determined for each of the CDAI-based improvement measures according to univariable logistic regression analyses. A stabilised IPTW was created based on PS estimations at baseline, 3, 6, 9 and 11 months and used as the weight for outcome modelling at 12 months.

†Defined as achieving and maintaining ≥50% improvement of CDAI (CDAI50), ≥70% (CDAI70) and ≥85% (CDAI85) during the 12-month treatment.

‡Defined as CDAI reduction >12 for patients starting with a high CDAI and CDAI reduction >6 for those starting with a moderate CDAI at 12 months of treatment.

bDMARD, biological disease-modifying antirheumatic drug; CDAI, clinical disease activity index; IPTW, inverse probability of treatment weighting; MCID, minimal clinically important difference; RA, rheumatoid arthritis.